Genetic Testing for Prostate Cancer:
What Every Patient Should Know in 2026
A new wave of guidelines, approved therapies, and patient-centered tools is making germline genetic testing a standard part of prostate cancer care — but most men still haven't been tested. Here's what you need to know.
Bottom Line Up Front (BLUF)
Germline genetic testing — a blood or saliva test that looks for inherited gene changes — has become a cornerstone of prostate cancer care in 2025–2026. Both ASCO and NCCN now recommend it broadly for men with metastatic, high-risk, or locally advanced disease, and for men with relevant family histories. Knowing your genetic status can guide which treatments will work best for you (including PARP inhibitors like olaparib and rucaparib), alert your sons, brothers, and other relatives to start screening earlier, and reveal whether you may be at risk for other cancers. Despite these benefits, most men still haven't been tested. A new Australian research study confirms that patients know little about this testing and worry most about its impact on life insurance and their families. In the United States, federal law (GINA) protects you from genetic discrimination by health insurers and employers — but critically, life insurance, long-term care insurance, and disability insurance are not covered by GINA. Understanding what testing can and cannot do — and what protections you do and don't have — is the first step toward making an informed decision.
Why This Matters Now
Prostate cancer is the most commonly diagnosed cancer among men in many countries and, crucially, it is the most heritable of all the common cancers. Yet for decades, the field lagged far behind breast and ovarian cancer in using genetic information to guide treatment and family risk assessment. That has changed dramatically in the past few years.
Both of the two leading U.S. cancer guideline bodies — the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) — issued or updated major recommendations in 2025 calling for broader genetic testing in prostate cancer patients. The message from the experts: genetic testing is no longer just for patients with the most advanced disease. It is increasingly a standard-of-care tool at many stages of diagnosis.
"Genetic testing is no longer reactive — it's proactive. By expanding eligibility and embedding testing earlier in standard care pathways, patients and clinicians can have expanded discussions regarding treatment options and greater peace of mind when making treatment decisions."
A large, prospective U.S. study called the PROCLAIM trial tested an unselected population of prostate cancer patients — about half of whom did not meet older NCCN testing criteria — and found that roughly 7.7% of all patients had a meaningful inherited gene change. Importantly, that rate was nearly identical whether or not a patient met the older guidelines (8.8% vs. 6.6%), suggesting that limiting testing only to higher-risk patients misses a substantial number of men who could benefit.
What Is Germline Genetic Testing?
When your doctor mentions genetic testing for prostate cancer, they may be referring to one of two types:
Two Types of Genetic Tests in Prostate Cancer
- Germline testing — A blood or saliva test that looks for inherited gene changes you were born with and that every cell in your body carries. These are the changes you could pass on to your children. This is the focus of this article.
- Somatic (tumor) testing — A test of the cancer tissue itself to look for changes that occurred only in the tumor. These are not inherited and cannot be passed to family members, but they can still guide treatment choices.
Both types of testing provide valuable — and different — information. ASCO's 2025 guideline recommends that men with metastatic prostate cancer have both tests.
Germline testing typically looks at a panel of genes. The current NCCN guideline (Version 3.2025) identifies 11 genes associated with prostate cancer susceptibility and 19 genes related to how well a tumor responds to a class of drugs called PARP inhibitors. The most important genes to know about include:
Key Genes Tested in Prostate Cancer Germline Panels
- BRCA2 — The most important. Carries the strongest link to aggressive, lethal prostate cancer. BRCA2 mutations are associated with a fourfold higher risk of aggressive disease and dramatically better response to PARP inhibitors.
- BRCA1 — Also significant, though PARP inhibitor response appears weaker for BRCA1 than BRCA2.
- ATM — Associated with aggressive disease and some responsiveness to PARP inhibitors.
- PALB2, CHEK2 — Linked to elevated prostate cancer risk and part of the Hereditary Breast and Ovarian Cancer (HBOC) syndrome family.
- MLH1, MSH2, MSH6, PMS2 (Lynch syndrome genes) — Associated with mismatch repair deficiency, which may qualify patients for immunotherapy (pembrolizumab).
- HOXB13 — A prostate-specific susceptibility gene increasingly included in panels.
What Testing Can Do for You — and Your Family
There are several reasons why knowing your germline status matters:
1. Guiding your treatment. If you have a mutation in BRCA1, BRCA2, or certain other genes, you may be eligible for FDA-approved targeted therapies called PARP inhibitors. Olaparib (Lynparza) and rucaparib (Rubraca) are approved for men with metastatic castration-resistant prostate cancer (mCRPC) who carry these mutations. The clinical trial data is compelling: in the landmark PROfound trial, men with BRCA1 or BRCA2 mutations who received olaparib had a median of 9.8 months before disease progression, compared to 3.0 months for those on standard hormonal therapy — more than a threefold improvement. The benefit was particularly striking for BRCA2 carriers. In the TRITON3 trial, men with BRCA mutations treated with rucaparib had 11.2 months of progression-free survival versus 6.4 months on other standard treatments. Newer combination approaches pairing PARP inhibitors with androgen receptor-pathway inhibitors (like enzalutamide or abiraterone) are showing even longer survival benefits in ongoing trials.
2. Getting the right surveillance. Men with certain gene mutations should start prostate cancer screening earlier — at age 40 — rather than the standard 50–55 years. If you already have prostate cancer and carry a BRCA2 mutation, it signals a higher risk of cancer spreading, which may affect decisions about active surveillance versus treatment.
3. Protecting your family. This is consistently what patients themselves say matters most to them. An inherited gene mutation can be shared with your sons, brothers, and other blood relatives. Knowing your status means they can consider "cascade testing" — getting tested themselves — and, if positive, start screening earlier. This is potentially life-saving information for your family.
4. Revealing other cancer risks. BRCA2 and BRCA1 mutations are not prostate-only risks. They raise your own risk of pancreatic cancer and melanoma, among others. Female relatives who carry these mutations face significantly elevated breast and ovarian cancer risk. Knowing you carry such a mutation opens a door to comprehensive cancer surveillance for your whole family.
What a New Study Found: Patients Don't Know Enough — and Are Worried About Insurance
A study just published in early April 2026 from the Menzies Institute for Medical Research at the University of Tasmania gives us important insight into how real patients think and feel about this testing. Led by Dr. Kelsie Raspin and colleagues, the study used focus groups with 20 prostate cancer patients and then tested a new "Precision Medicine in Prostate Cancer Information Toolkit" with patients, family members, and healthcare providers.
The findings were sobering — and instructive for all of us:
Key Findings from the Raspin et al. 2026 Study
- Nearly half of patients had heard the term "precision medicine" but did not understand what it means.
- While all patients had heard of genetic testing, almost none understood its specific application to prostate cancer.
- The strongest motivation for wanting testing was to protect family members — specifically to tell sons and brothers so they can be monitored.
- The biggest concern was insurance discrimination — particularly the fear that a positive result would affect their children's ability to get life insurance.
- Other concerns included anxiety about the decision-making process itself, cost, and equity of access.
- Patients also struggled to understand technical terms like "panel" (as in, a genetic testing panel of multiple genes) and "PARP inhibitors."
- When a patient-education toolkit was evaluated, patients found it less useful than healthcare providers did — suggesting that materials need to be anchored in patients' lived experiences and written around their real concerns, not just medical facts.
Voices from the Focus Groups
"I think, for my son, if he was aware that he had the markers of
an abnormal prostate, then it would flag him to be monitored more
closely than to live life blindly without — and then finding that out
too late [when the cancer has spread]."
"I do have one concern — the implications for health insurance."
"The insurance scenario is real. If I had got the wrong answer with
the testing to me in relation to what genes my daughters might've
inherited, there might be a point where they're seeking insurance, they
have to disclose that and the answer is, 'No, you can't have
insurance.'"
"And you need to make it simplistic because it's going to blokes and blokes will just — won't read it."
The Insurance Question: What GINA Does and Does Not Cover
Insurance discrimination is one of the most common reasons patients hesitate to pursue genetic testing, so it is essential to understand exactly what the law says — and where the gaps are.
In the United States, the Genetic Information Nondiscrimination Act of 2008 (GINA) is the primary federal protection. Here is what it covers:
What GINA Protects — and What It Doesn't
- GINA DOES protect you: Health insurance companies (covered by HIPAA) cannot use your genetic test results to deny you coverage, set your premiums, or refuse to enroll you. Employers (companies with 15 or more employees) cannot use genetic information in hiring, firing, promotions, or pay decisions.
- GINA does NOT protect you from: Life insurance companies, long-term care insurance companies, and disability insurance companies. These insurers can legally ask about your genetic test results and use them in underwriting decisions in most states. This is the gap that patient advocates have highlighted for years.
- Important nuance: GINA protects you based on genetic information alone. However, once you have an actual cancer diagnosis, that is a manifest disease — a pre-existing condition — and different rules apply (governed by the ACA, not GINA).
- State protections vary: Fewer than half of U.S. states have laws that extend additional protections beyond GINA into the life insurance space. Check your state's laws.
A February 2026 article in the journal Science underscores that pressure is building worldwide to close this life insurance gap. Australia, for example, announced in 2024 that it would ban the use of genetic test results in life insurance underwriting entirely — though as of March 2026, that legislation had not yet been enacted. The U.S. National Council of Insurance Legislators proposed a model state-level act in October 2025 that would restrict life insurers' use of genetic information, but as of early 2026 this remains a patchwork of state-by-state decisions.
The bottom line for IPCSG members: if you do not yet have life, disability, or long-term care insurance and are considering germline testing, it may be worth talking with a financial advisor or insurance broker before getting tested. If you already have those policies in force, GINA and existing contracts generally protect you. Consulting a genetic counselor before testing is always recommended — they can help you navigate these concerns.
Who Should Be Tested? The 2025–2026 Guidelines
The NCCN (Version 3.2025 / Version 1.2026) and ASCO's 2025 guideline both recommend germline testing for a broad and expanding group of prostate cancer patients. The following are the general categories:
Who the Guidelines Say Should Be Tested
- All men with metastatic prostate cancer (any stage of metastasis)
- Men with very high-risk or high-risk localized disease (high clinical stage, Grade Group 4–5, or PSA >20 at diagnosis)
- Men with biochemical recurrence meeting certain risk or family history scenarios
- Men diagnosed with prostate cancer at age 55 or younger
- Men of Ashkenazi Jewish ancestry with prostate cancer or qualifying family history
- Men with a family history fitting Hereditary Breast and Ovarian Cancer (HBOC) or Lynch syndrome criteria
- Men with three or more close blood relatives with prostate cancer (any grade) or breast cancer on the same side of the family
Note: These criteria continue to evolve. Many experts are now advocating for universal testing of all prostate cancer patients, given that guideline-based criteria miss a significant portion of men with actionable mutations.
Why So Many Patients Still Haven't Been Tested
Despite guidelines that have existed since at least 2019, testing rates remain alarmingly low. A nationwide U.S. study found that only about 18% of commercially insured patients and 14% of veterans who qualified for testing actually received it within one year of diagnosis. A survey of urologists found that one in three do not perform genetic testing or refer their patients to a genetic counselor at all.
The barriers are multiple. Genetic counselors are in short supply, and the volume of patients who should be tested has outpaced available counseling capacity. Patients who are uninsured, on Medicaid, or in rural areas face greater access hurdles. Cost can be a barrier, though many commercial labs have programs to reduce out-of-pocket expenses, and major insurers increasingly cover testing for eligible patients.
There is also a serious equity gap by race. Multiple studies have shown that Black men with prostate cancer — who already face higher mortality rates — are significantly less likely to receive germline testing than White men. A 2024 study found that commercially insured Black men had a 27% lower rate of completing genetic testing compared to White men (adjusted hazard ratio 0.73), though this disparity largely disappeared in the Veterans Health Administration, where access barriers were equalized. This suggests that when financial and structural barriers are removed, racial disparities in testing can be substantially reduced.
The practical implication: if your doctor has not yet discussed genetic testing with you, it is reasonable — and encouraged — to ask about it at your next appointment.
What to Expect from the Testing Process
Germline testing is usually straightforward. It typically requires a blood draw or a saliva sample. A panel of relevant genes is analyzed, and results are usually available in two to four weeks.
Results come in several forms:
Understanding Your Results
- Pathogenic or likely pathogenic variant (P/LP): A gene change that is known or strongly believed to increase cancer risk or affect treatment options. This is an "actionable" result.
- Negative (no pathogenic variant found): No significant inherited gene change was found. This is generally reassuring but does not eliminate all risk.
- Variant of uncertain significance (VUS): A gene change was found, but scientists don't yet know whether it is harmful or harmless. This can be frustrating. VUS classifications are updated regularly as more data accumulates — sometimes a VUS is later reclassified as either clearly harmful or clearly benign. A VUS alone should not drive treatment decisions.
Importantly, a genetic counselor can help you understand what your specific result means — not just medically, but for your family and your peace of mind. If you test positive for an actionable mutation, a genetics professional should review what that means for cancer surveillance, cascade family testing, and treatment eligibility.
New Resources for Patients
In November 2025, the Prostate Cancer Foundation (PCF) and the Urology Care Foundation jointly launched a free, interactive online guide specifically designed to help patients and families understand somatic and germline genetic testing for advanced prostate cancer. The guide covers what the tests are, how to understand your results, what questions to ask your doctor, the role of genetic counselors, and practical matters like insurance coverage and cost. It is available at pcf.org/somatic-and-germline-genetic-testing-guide.
The Australian "Precision Medicine in Prostate Cancer Information Toolkit" described in the Raspin et al. study above is undergoing revision based on patient feedback, with the next version expected to include real patient stories, clearer guidance on insurance and cost issues, and better plain-language explanations of complex terms. Such co-designed, patient-centered tools represent the future of genetic literacy in prostate cancer care.
Five Questions to Ask Your Doctor
Ask Your Doctor or Specialist
- "Based on my diagnosis and family history, do I qualify for germline genetic testing?"
- "Should I also have somatic (tumor) testing? What additional information would that give me?"
- "If I test positive for a BRCA2 or other mutation, what treatment options would that open up for me?"
- "Can you refer me to a genetic counselor who can help me interpret my results and talk to my family?"
- "What are the insurance implications of testing, and is there financial assistance available to cover the cost?"
The Big Picture: Why This Moment Matters
We are at a genuine inflection point in prostate cancer care. The identification of inherited gene mutations is no longer just a research tool — it directly shapes which treatments are offered, when screening begins for your relatives, and how aggressively a cancer is monitored. PARP inhibitors, guided by genetic testing, are providing meaningful extensions of life for men with advanced disease. Immunotherapy options exist for men whose tumors show mismatch repair deficiency. Combination therapies being tested now may push those benefits even further.
Yet the science only helps patients who actually get tested. The barriers — lack of awareness, insurance anxiety, shortage of genetic counselors, access disparities, and cost — are real. Advocacy organizations like IPCSG play a crucial role in closing the knowledge gap and helping men and their families make informed, empowered decisions.
If you take away one thing from this article, let it be this: ask about genetic testing at your next appointment. Whether the result is positive, negative, or uncertain, that information is yours — and it could matter enormously, for you and for the people you love.
Verified Sources — Formal Citations
- Raspin K, Bartlett L, Makin J, Wilson R, Butorac K, Roydhouse
J, Dickinson JL. "What tools do men need to make an informed decision
about germline genetic testing for prostate cancer: A qualitative and
survey study." medRxiv preprint. Published online April 2, 2026. doi:10.64898/2026.03.27.26349466
https://doi.org/10.64898/2026.03.27.26349466 - Loeb S, Vadaparampil ST, Giri VN. "Germline testing for prostate cancer: current state and opportunities for enhanced access." EBioMedicine. 2025;116:105705. [Accepted April 2, 2025; Collection June 2025]
https://pmc.ncbi.nlm.nih.gov/articles/PMC12148599/ - Myriad Genetics. "Using Prostate Cancer Gene Testing to Guide
Treatment Decisions: Insights as We Head into 2026." Published October
3, 2025.
https://myriad.com/myriad-genetics-blog/using-prostate-cancer-gene-testing-to-guide-treatment-decisions-insights-as-we-head-into-2026/ - Yu EY, Rumble RB, Agarwal N, et al. "Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline." Journal of Clinical Oncology. 2025;43(6):748–758. Published January 9, 2025. doi:10.1200/JCO-24-02608
https://ascopubs.org/doi/10.1200/JCO-24-02608 - Shore N, Nielsen SM, Esplin ED, Antonarakis ES, et al.
"Implementation of Universal Germline Genetic Testing Into Standard of
Care for Patients With Prostate Cancer: The Time Is Now." JCO Oncology Practice. 2025;21(6):747–753. Published online December 19, 2024. doi:10.1200/OP-24-00626
https://ascopubs.org/doi/10.1200/OP-24-00626 - Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines. The Prostate.
2025. Open access. Based on NCCN Genetic/Familial High-Risk Assessment:
Breast, Ovarian, Pancreatic, and Prostate Version 3.2025 (March 6,
2025).
https://pmc.ncbi.nlm.nih.gov/articles/PMC12278705/ - Paller CJ. "Germline and Somatic Genetic Testing in Advanced
Prostate Cancer: Practical Considerations and Challenges." Presented at
ESMO 2025. Published October 21, 2025.
https://www.urotoday.com/conference-highlights/esmo-2025/… - Prostate Cancer Foundation (PCF) and Urology Care Foundation.
"Somatic and Germline Genetic Testing for Patients with Advanced
Prostate Cancer — What You Should Know." Interactive guide and website.
Launched November 21, 2025.
https://www.pcf.org/somatic-and-germline-genetic-testing-guide/
Press release: https://www.pcf.org/pcf-launches-new-genetic-testing-guide/ - de Bono J, Mateo J, Fizazi K, et al. "Olaparib for Metastatic Castration-Resistant Prostate Cancer." New England Journal of Medicine. 2020;382:2091–2102. [PROfound trial]
https://www.nejm.org/doi/full/10.1056/NEJMoa1911440 - Mateo J, de Bono JS, Fizazi K, et al. "Olaparib for the
Treatment of Patients With Metastatic Castration-Resistant Prostate
Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial." Journal of Clinical Oncology. Published online November 14, 2023. doi:10.1200/JCO.23.00339
https://ascopubs.org/doi/10.1200/JCO.23.00339 - Fizazi K, Piulats JM, Reaume MN, et al. "Rucaparib or Physician's Choice in Metastatic Prostate Cancer." [TRITON3 trial.] New England Journal of Medicine. 2023;388:719–732.
https://www.nejm.org/doi/full/10.1056/NEJMoa2214676 - NCI Cancer Currents Blog. "FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer." National Cancer Institute.
https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-olaparib-rucaparib-prostate-cancer - Recalde M, et al. "PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis." Cancers.
PMC. Collection July 2025. [Includes TALAPRO-2 data and ASCO GU 2025
talazoparib+enzalutamide results.] doi:10.3390/cancers17141896
https://pmc.ncbi.nlm.nih.gov/articles/PMC12298444/ - Prince AER, et al. "Genetic testing and insurance
implications: Surveying the US general population about discrimination
concerns and knowledge of the Genetic Information Nondiscrimination Act
(GINA)." Risk Management and Insurance Review. 2021;24(4):341–365. PMC9165621.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9165621/ - National Human Genome Research Institute. "Genetic Discrimination." Updated January 2022.
https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination - American Medical Association. "Genetic Discrimination." AMA Policy Page.
https://www.ama-assn.org/public-health/population-health/genetic-discrimination - Eckel T. "Genetic information in insurance: Guiding questions for state regulation." Science.
2026;391:872–874. doi:10.1126/science.aee2317. [Published February
2026; includes reference to Australia's Treasury Laws Amendment Bill
2025 and the NCOIL proposed Model Act, October 2025.]
https://www.science.org/doi/10.1126/science.aee2317 - FORCE (Facing Our Risk of Cancer Empowered). "Protections
Against Pre-existing Conditions vs. Genetic Discrimination." Updated
March 2026. [Includes February 4, 2026 FORCE submission to NCOIL on life
insurance genetic information model act.]
https://www.facingourrisk.org/…/protections-against-genetic-discrimination… - Briggs LG, et al. "Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review." JCO Oncology Practice. 2023. doi:10.1200/OP.22.00634
https://ascopubs.org/doi/10.1200/OP.22.00634 - Weise N, Shaya J, Javier-Desloges J, et al. "Disparities in germline testing among racial minorities with prostate cancer." Prostate Cancer and Prostatic Diseases. 2022;25(3):403–410. PMC8590439.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8590439/ - Giri VN, et al. "Germline Variant Spectrum Among African
American Men Undergoing Prostate Cancer Germline Testing: Need for
Equity in Genetic Testing." JCO Precision Oncology. 2022. PMC9200399.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9200399/ - Ambrose AM, et al. "Racial Differences in Germline Genetic
Testing Completion Among Males With Pancreatic, Breast, or Metastatic
Prostate Cancers." PubMed. Published April 17, 2024. doi:10.1200/OP.23.00551
https://pubmed.ncbi.nlm.nih.gov/38631387/ - Giri VN, et al. "Adaptation of the socioecological model to
address disparities in engagement of Black men in prostate cancer
genetic testing." BMC Public Health. 2024. doi:10.1186/s12889-024-20008-8
https://link.springer.com/article/10.1186/s12889-024-20008-8
Comments
Post a Comment